[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648612":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":29,"locations":37,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuation group",null,"Participants who have continued at least one antifibrotic therapy for a specific period (≥6 months) at the time of enrollment.",[13],"Drug: Antifibrotic therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Discontinuation group","Participants who have completely ceased all antifibrotic therapies for at least 1 month prior to enrollment.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Antifibrotic therapy","As per product label prescribed by treating physician",[9,15],[25],"Antifibrotic therapies include pirfenidone, nintedanib or nerandomilast.",[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":36,"role":32,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[38],{"facility":39,"status":10,"city":40,"state":10,"zip":10,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"Mebix, Inc.","Tokyo","Japan","JP",{"type":44,"coordinates":45},"Point",[46,47],139.69171,35.6895,{"lat":47,"lon":46},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100648612","antifibrotic-therapy-decision-making-in-pulmonary-fibrosis-100648612",false,"NCT07722507","Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis","Understanding Pulmonary Fibrosis Through Web-Based Qualitative In-Depth Interviews on Antifibrotic TheRapy Decision-Making","UPWARD","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be eligible for inclusion in this study:\n\n1. Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).\n2. Participants who are ≥18 years of age at the time of providing informed consent via the web-based system.\n3. Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician.\n4. Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast.\n5. Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE).\n\n   * Discontinuation group only\n\n1\\) Participants who have not received AF therapy for at least 1 month prior to enrollment.\n\n2\\) Participants whose AF therapy was discontinued within 6 months prior to enrollment.\n\n3\\) Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE.\n\n* Continuation group only\n\n  1. Participants who feel or have felt burdened by the experienced AE.\n  2. Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment.\n\n     Exclusion Criteria:\n\n     Participants meeting any of the following criteria will be excluded from the study:\n\n  \u003C!-- -->\n\n  1. Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies).\n  2. Participants who have undergone lung transplantation.\n* Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).","ALL","18 Years",{"count":62,"type":63},40,"ESTIMATED","OBSERVATIONAL","This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.",[67,68,69],"Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Progressive Pulmonary Fibrosis",[21,71,72,73],"Pulmonary fibrosis (PF)","Idiopathic pulmonary fibrosis (IPF)","Progressive pulmonary fibrosis (PPF)","NOT_YET_RECRUITING","2026-07-20",{"date":77,"type":78},"2026-07-23","ACTUAL",{"date":80,"type":63},"2026-08-01",{"date":82,"type":63},"2027-05-31",{"name":5,"class":6},1]